Pittenger & Anderson Inc. grew its holdings in shares of Celgene Corporation (NASDAQ:CELG) by 9.0% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 45,362 shares of the biopharmaceutical company’s stock after purchasing an additional 3,736 shares during the quarter. Pittenger & Anderson Inc.’s holdings in Celgene Corporation were worth $5,891,000 at the end of the most recent quarter.
Several other institutional investors have also modified their holdings of CELG. Karp Capital Management Corp acquired a new stake in shares of Celgene Corporation during the 1st quarter worth $49,750,000. Tdam USA Inc. increased its holdings in shares of Celgene Corporation by 2.1% during the 1st quarter. Tdam USA Inc. now owns 27,084 shares of the biopharmaceutical company’s stock worth $3,370,000 after buying an additional 570 shares during the last quarter. YorkBridge Wealth Partners LLC increased its holdings in shares of Celgene Corporation by 27.6% during the 1st quarter. YorkBridge Wealth Partners LLC now owns 11,915 shares of the biopharmaceutical company’s stock worth $1,475,000 after buying an additional 2,574 shares during the last quarter. Wedbush Securities Inc. increased its holdings in shares of Celgene Corporation by 9.9% during the 1st quarter. Wedbush Securities Inc. now owns 30,877 shares of the biopharmaceutical company’s stock worth $3,842,000 after buying an additional 2,778 shares during the last quarter. Finally, Engineers Gate Manager LP acquired a new stake in shares of Celgene Corporation during the 1st quarter worth $4,250,000. 79.16% of the stock is currently owned by institutional investors.
A number of research firms have recently commented on CELG. Oppenheimer Holdings, Inc. restated an “outperform” rating and set a $175.00 price objective on shares of Celgene Corporation in a report on Wednesday, August 9th. Vetr upgraded Celgene Corporation from a “buy” rating to a “strong-buy” rating and set a $148.32 price objective for the company in a report on Wednesday, August 16th. Cantor Fitzgerald restated a “buy” rating and set a $162.00 price objective on shares of Celgene Corporation in a report on Tuesday, September 26th. Jefferies Group LLC reiterated a “buy” rating and issued a $160.00 price target on shares of Celgene Corporation in a report on Monday, July 31st. Finally, Piper Jaffray Companies reiterated a “neutral” rating and issued a $133.00 price target on shares of Celgene Corporation in a report on Monday, October 23rd. One research analyst has rated the stock with a sell rating, eleven have given a hold rating, nineteen have assigned a buy rating and two have issued a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $139.64.
In other Celgene Corporation news, Director Gilla Kaplan sold 9,250 shares of the firm’s stock in a transaction that occurred on Tuesday, September 12th. The shares were sold at an average price of $141.56, for a total value of $1,309,430.00. Following the sale, the director now owns 85,551 shares in the company, valued at $12,110,599.56. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Terrie Curran sold 1,727 shares of the firm’s stock in a transaction that occurred on Monday, September 25th. The shares were sold at an average price of $143.89, for a total transaction of $248,498.03. Following the completion of the sale, the insider now owns 3,925 shares in the company, valued at approximately $564,768.25. The disclosure for this sale can be found here. Insiders sold 20,227 shares of company stock worth $2,843,956 in the last 90 days. 0.95% of the stock is owned by company insiders.
TRADEMARK VIOLATION WARNING: “Celgene Corporation (CELG) Holdings Lifted by Pittenger & Anderson Inc.” was first published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this piece of content on another website, it was copied illegally and republished in violation of U.S. & international trademark & copyright law. The correct version of this piece of content can be accessed at https://www.chaffeybreeze.com/2017/11/14/celgene-corporation-celg-holdings-lifted-by-pittenger-anderson-inc.html.
Celgene Corporation (NASDAQ:CELG) opened at $101.16 on Tuesday. The company has a quick ratio of 3.52, a current ratio of 3.65 and a debt-to-equity ratio of 1.31. Celgene Corporation has a twelve month low of $94.55 and a twelve month high of $147.17. The stock has a market cap of $80,574.02, a PE ratio of 15.99, a price-to-earnings-growth ratio of 0.79 and a beta of 1.79.
Celgene Corporation (NASDAQ:CELG) last announced its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.91 EPS for the quarter, beating the consensus estimate of $1.87 by $0.04. Celgene Corporation had a net margin of 27.36% and a return on equity of 63.80%. The company had revenue of $3.29 billion for the quarter, compared to analyst estimates of $3.42 billion. During the same quarter last year, the business earned $1.58 earnings per share. Celgene Corporation’s revenue was up 10.2% compared to the same quarter last year. equities analysts expect that Celgene Corporation will post 6.67 EPS for the current fiscal year.
Celgene Corporation Profile
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with MarketBeat.com's FREE daily email newsletter.